Interest of a Tongue Strength Measurement in the Screening for Sarcopenia in Hospitalized Elderly Patients

NCT03417609 | Completed

• 1 other identifier: CHUB-sarcopenia-tongue
• Study Type: observational
• Target: 110
• Locations: 1 country
• Sites: 1

Brief Summary

Sarcopenia is a syndrome characterized by a progressive and generalized loss of skeletal muscle mass, strength and function that increases the risk of physical dependence, impaired quality of life and mortality. This is a major public health problem. Indeed, its prevalence has been estimated at 63.8% for elderly patients hospitalized in acute geriatric unit. Several methods of sarcopenia screening exist at present. The European Working Group on Sarcopenia in Older People (EWGSOP) proposes to carry out three examinations for the diagnosis of sarcopenia: the Dual-Energy X-ray Absorptiometry (DEXA) test and two motor tests (walking speed and hand test). These measurements have already been evaluated and validated. They are reliable, inexpensive and easily achievable in clinical routine. Recent studies have shown that decreased muscle mass and / or strength could be associated with dysphagia. Indeed, many muscles of the head and neck are simultaneously solicited for swallowing coordination. This suggests that a reduction in the mass or strength of these muscles could impact the swallowing function. The investigator's hypothesize that loss of lingual muscle strength may be associated with sarcopenia. The study will measure the tongue strength using the Iowa Oral Performance Instrument (IOPI) in a geriatric population with or without sarcopenia.

• Determine the incidence of lingual hypotonia in hospitalized elderly sarcopenia patients.
• To compare the sensitivity, the specificity of the measurement of the force of the tongue with the usual measures proposed by the EWGSOP in the context of screening for sarcopenia.

Conditions

Sarcopenia

Keywords

Sarcopenia; Tongue strength

Outcome Measures

Primary Outcomes (1)

• Tongue strength

  The Iowa Oral Performance Instrument is a validated device for assessing the strength of the tongue. This involves placing the tip of a tube in the mouth and asking the patient to exert pressure on it. Thus, a pressure measurement expressed in kPa makes it possible to objectify the tongue strength.

  6 months

Secondary Outcomes (7)

• Pre-Albumin concentration

  6 months

• Albumin concentration

  6 months

• Mini Mental State Examination (MMSE) score

  6 months

• Minimal nutritional assessment (MNA-SF) score

  6 months

• Skeletal Mass Muscle Index

  6 months

Study Arms (2)

Sarcopenia

Elderly patients with sarcopenia

Device: Tongue strength measurement; Procedure: Blood sampling; Diagnostic Test: Mini Mental State Examination (MMSE); Diagnostic Test: Minimal nutritional assessment (MNA-SF); Diagnostic Test: Dual-energy x-ray absorptiometry (DEXA); Device: Dynamometer (Hand grip ); Diagnostic Test: Walking speed

Control

Elderly patients without sarcopenia

Device: Tongue strength measurement; Procedure: Blood sampling; Diagnostic Test: Mini Mental State Examination (MMSE); Diagnostic Test: Minimal nutritional assessment (MNA-SF); Diagnostic Test: Dual-energy x-ray absorptiometry (DEXA); Device: Dynamometer (Hand grip ); Diagnostic Test: Walking speed

Interventions

Tongue strength measurement DEVICE

The Iowa Oral Performance Instrument is a validated device for assessing the strength of the tongue. This involves placing the tip of a tube in the mouth and asking the patient to exert pressure on it.

Control; Sarcopenia

Blood sampling PROCEDURE

Blood sampling

Control; Sarcopenia

Mini Mental State Examination (MMSE) DIAGNOSTIC_TEST

Also called Folstein test, it is an assessment of the patient cognitive and memory functions. It detects cognitive disorders or dementia. The MMSE is quickly realizable and explores several cognitive functions through 30 questions divided into 7 items.

Control; Sarcopenia

Minimal nutritional assessment (MNA-SF) DIAGNOSTIC_TEST

The minimal nutritional assessment - short form is a simple, non - invasive and validated scale for the detection of malnutrition in the elderly patient.

Control; Sarcopenia

Dual-energy x-ray absorptiometry (DEXA) DIAGNOSTIC_TEST

Dual-energy x-ray absorptiometry (DEXA) is the imaging technique recommended for the diagnosis of sarcopenia.

Control; Sarcopenia

Dynamometer (Hand grip ) DEVICE

By placing a dynamometer in the patient's hand and asking him to apply maximum pressure to it, the muscular strength of the extremities of the limbs is estimated.

Control; Sarcopenia

Walking speed DIAGNOSTIC_TEST

Walking speed evaluates the muscular performance. The seated patient must get up and walk a distance of 6 meters as quickly as possible without the help of a third party.

Control; Sarcopenia

Eligibility Criteria

• Age: 65 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Older Adult (65+)
• Sampling Method: Non-Probability Sample

Study Population

Patients hospitalized in an acute geriatric unit within the CHU Brugmann.

You may qualify if:

• Patients hospitalized in an acute geriatric unit within the CHU Brugmann.

You may not qualify if:

• None

Sponsors & Collaborators

• Murielle Surquin: lead

Study Sites (1)

CHU Brugmann

Brussels, Belgium

Location

MeSH Terms

Conditions

Sarcopenia

Interventions

Blood Specimen Collection; Absorptiometry, Photon; Walking Speed

Condition Hierarchy (Ancestors)

Muscular Atrophy; Neuromuscular Manifestations; Neurologic Manifestations; Nervous System Diseases; Atrophy; Pathological Conditions, Anatomical; Pathological Conditions, Signs and Symptoms; Signs and Symptoms

Intervention Hierarchy (Ancestors)

Specimen Handling; Clinical Laboratory Techniques; Diagnostic Techniques and Procedures; Diagnosis; Punctures; Surgical Procedures, Operative; Investigative Techniques; Radiography; Diagnostic Imaging; Densitometry; Photometry; Chemistry Techniques, Analytical; Gait; Physical Examination; Walking; Locomotion; Movement; Musculoskeletal Physiological Phenomena; Musculoskeletal and Neural Physiological Phenomena

Study Officials

• Alexandrine de Buck van Overstraeten, MD

  CHU Brugmann

  PRINCIPAL INVESTIGATOR

Study Design

• Study Type: observational
• Observational Model: COHORT
• Time Perspective: PROSPECTIVE
• Sponsor Type: OTHER
• Responsible Party: SPONSOR INVESTIGATOR
• PI Title: Head of clinic

Study Record Dates

• First Submitted: January 25, 2018
• First Posted: January 31, 2018
• Study Start: February 7, 2018
• Primary Completion: January 1, 2019
• Study Completion: January 1, 2019
• Last Updated: April 4, 2019

Record last verified: 2019-04

Data Sharing

• IPD Sharing: Will not share

Locations

BE (1)